SCHEMBL19463510

SCHEMBL19463510

CCOC(=O)c1cnc2c(Br)c(C)nn2c1C(F)(F)F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.56
▸ GAA P10253 2/20 0.56
▸ KDM4E B2RXH2 8/20 0.49
▸ MAPT P10636 3/20 0.49
▸ HSD17B10 Q99714 3/20 0.49
▸ TSHR P16473 1/20 0.47
▸ NPC1 O15118 3/20 0.45
▸ RAB9A P51151 3/20 0.45
▸ HPGD P15428 2/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ CSNK1D P48730 1/20 0.44
▸ ALOX15 P16050 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ MEN1 O00255 2/20 0.42
▸ FOS P01100 2/20 0.41
▸ JUN P05412 2/20 0.41
▸ NFKB1 P19838 2/20 0.41
▸ NFKB2 Q00653 2/20 0.41
▸ RELA Q04206 2/20 0.41
▸ CASP1 P29466 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19464269 0.84 ALDH1A1 (0.40) ALDH1A1GAAKDM4EMAPTNPC1
SCHEMBL19492633 0.83 KDM4E (0.53) ALDH1A1KDM4EMAPTHSD17B10TSHR
SCHEMBL19492504 0.81 KDM4E (0.56) ALDH1A1KDM4EMAPTHSD17B10TSHR
SCHEMBL19464037 0.81 KDM4E (0.52) ALDH1A1KDM4EMAPTHSD17B10TSHR
SCHEMBL19492634 0.81 KDM4E (0.51) ALDH1A1KDM4EMAPTHSD17B10TSHR
SCHEMBL19463513 0.80 KDM4E (0.50) ALDH1A1KDM4EMAPTHSD17B10TSHR
SCHEMBL19463663 0.80 KDM4E (0.50) ALDH1A1KDM4EMAPTHSD17B10TSHR
SCHEMBL19492617 0.78 KDM4E (0.48) ALDH1A1KDM4EMAPTHSD17B10TSHR
SCHEMBL19464210 0.78 KDM4E (0.48) ALDH1A1KDM4EMAPTHSD17B10TSHR
SCHEMBL19464226 0.76 GAA (0.53) ALDH1A1GAAKDM4EMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3442974-B1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2023-06-07 — — EP disclosed
EP-3442974-B1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2023-06-07 — — EP disclosed
US-11001590-B2 Pyrazolopyrimidine derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-05-11 — — US disclosed
US-11001590-B2 Pyrazolopyrimidine derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-05-11 — — US disclosed
US-10934301-B2 Pyrazolopyrimidine derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-03-02 — — US disclosed
US-10934301-B2 Pyrazolopyrimidine derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-03-02 — — US disclosed
US-20200299299-A1 NEW PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2020-09-24 — — US disclosed
US-20200299299-A1 NEW PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2020-09-24 — — US disclosed
US-20200239482-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2020-07-30 — — US disclosed
US-20200239482-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2020-07-30 — — US disclosed
US-10604525-B2 Pyrazolopyrimidine derivatives BAYAL ANIMAL HEALTH GMBH (DE) 2020-03-31 — — US disclosed
US-20190071447-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2019-03-07 — — US disclosed
US-20190071447-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2019-03-07 — — US disclosed
EP-3442974-A1 PYRAZOLOPYRIMIDINE DERIVATIVES Bayer Animal Health GmbH (DE) 2019-02-20 — — EP disclosed
WO-2017178416-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2017-10-19 — — WO disclosed
WO-2017178416-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2017-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10604525-B2 Pyrazolopyrimidine derivatives P2RX5, RECQL, P2RX1 ALDH1A1 1297/4885GAA 2024/4885KDM4E 1438/4885
US-11001590-B2 Pyrazolopyrimidine derivatives P2RX5, RECQL, P2RX1 ALDH1A1 1228/4885GAA 2003/4885KDM4E 1445/4885
US-20190071447-A1 PYRAZOLOPYRIMIDINE DERIVATIVES P2RX5, RECQL, P2RX1 ALDH1A1 1297/4885GAA 2024/4885KDM4E 1438/4885
US-20200239482-A1 PYRAZOLOPYRIMIDINE DERIVATIVES P2RX5, RECQL, P2RX1 ALDH1A1 1228/4885GAA 2003/4885KDM4E 1445/4885
US-10934301-B2 Pyrazolopyrimidine derivatives P2RX5, RECQL, P2RX1 ALDH1A1 1228/4885GAA 2003/4885KDM4E 1445/4885
US-20200299299-A1 NEW PYRAZOLOPYRIMIDINE DERIVATIVES P2RX5, RECQL, P2RX1 ALDH1A1 1241/4885GAA 1930/4885KDM4E 1658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback